Abstract: A method of fixing a low-molecular compound to a solid-phase support, by bringing a solution containing a low-molecular compound into contact with a solid-phase support having a photoreactive compound bonded to the surface, evaporating the solution containing a low-molecular compound to dryness, in the state of being in contact with the solid-phase support, and irradiating the solid-phase support with light to form a covalent bond between the photoreactive compound and the low-molecular compound. This fixing method enables a low-molecular compound to be fixed to a solid-phase support without the aid of a functional group.

Abstract: A compound represented by the general formula (I): (I) wherein R represents linear, branched, or cyclic alkyl or aryl; a process for producing the compound; and an antitumor agent containing the compound as an active ingredient.

Abstract: A compound represented by the following formula (I) or a salt thereof which has excellent antitumor activity and angiogenesis inhibitory action in a low oxygen condition, and a medicament such as an antitumor agent and an anti-inflammatory agent which comprises the compound or a physiologically acceptable salt thereof as an active ingredient.

Abstract: A method of label-free observing of any interaction between biomolecule and substance immobilized on a metal substrate, characterized in that the substance is immobilized on the metal substrate by a covalent bond through photoreaction.

Abstract: A method of fixing a low-molecular compound to a solid-phase support, which comprises a step in which a solution containing a low-molecular compound is brought into contact with a solid-phase support having a photoreactive compound bonded to the surface, a step in which the solution containing a low-molecular compound is evaporated to dryness in the state of being in contact with the solid-phase support, and a step in which the solid-phase support is irradiated with light to form a covalent bond between the photoreactive compound and the low-molecular compound. This fixing method enables a low-molecular compound to be fixed to a solid-phase support without the aid of a functional group.

Abstract: A compound represented by formula (I) wherein R1 represents hydrogen atom and R2 represents hydroxyl group, or R1 and R2 may combine together to represent oxo group or oxime group; R3 represents hydrogen atom and R4 represents hydroxyl group, or R3 and R4 may combine together to represent oxo group or oxime group; R5 represents hydrogen atom and R6 represents hydroxyl group, or R5 and R6 may combine together to represent oxo group or oxime group; R7 represents hydrogen atom and R8 represents hydrogen atom, or R7 and R8 may combine together to represent oxo group or oxime group; R9 and R10 represent hydrogen atom, an alkyl group, or an alkenyl group.

Abstract: The present invention has an object to provide a novel therapeutic agent for hypercalcemia and bone diseases, and a novel compound capable of being used as an active ingredient of the therapeutic agent. The present invention is a therapeutic agent for hypercalcemia or bone diseases, comprising as an active ingredient a reveromycin A derivative represented by the general formula (I) or a pharmaceutically acceptable salt thereof. (R represents a hydroxyl-protecting group releasable under acidic conditions.

Abstract: In a conductive member having a support and provided thereon at least one cover layer, the cover layer has a surface layer, and the surface layer contains fine particles. In the surface layer, fine particles present at the surface-layer lower part corresponding to a range within 30% of the total layer thickness from the lowermost plane have an average particle diameter which is larger than the average particle diameter of fine particles present at the surface-layer upper part corresponding to a range within 30% of the total layer thickness from the uppermost plane. A process cartridge and an electrophotographic apparatus have such a conductive member.

Abstract: A compound represented by the general formula (I): (I) wherein R represents linear, branched, or cyclic alkyl or aryl; a process for producing the compound; and an antitumor agent containing the compound as an active ingredient.

Abstract: A compound represented by the following formula (I) or a salt thereof which has excellent antitumor activity and angiogenesis inhibitory action in a low oxygen condition, and a medicament such as an antitumor agent and an anti-inflammatory agent which comprises the compound or a physiologically acceptable salt thereof as an active ingredient.

Abstract: A compound represented by formula (I) wherein R1 represents hydrogen atom and R2 represents hydroxyl group, or R1 and R2 may combine together to represent oxo group or oxime group; R3 represents hydrogen atom and R4 represents hydroxyl group, or R3 and R4 may combine together to represent oxo group or oxime group; R5 represents hydrogen atom and R6 represents hydroxyl group, or R5 and R6 may combine together to represent oxo group or oxime group; R7 represents hydrogen atom and R8 represents hydrogen atom, or R7 and R8 may combine together to represent oxo group or oxime group; R9 and R10 represent hydrogen atom, an alkyl group, or an alkenyl group. The compound is useful as an active ingredient of a medicament having angiogenesis suppressive activity, apoptosis suppressive activity, and cell cycle inhibitory activity.

Abstract: A compound represented by the following formula (I) or a salt thereof and a medicament such as an angiogenesis inhibitor and an antitumor agent which comprises said compound or a physiologically acceptable salt thereof as an active ingredient.

Abstract: A mutant Plk protein having a mutation in C-terminal domain thereof specified by amino acid residues of from 439 to 603 of amino acid sequence of wild-type Plk protein wherein said mutation decreases affinity with Hsp90 protein, and a gene encoding said mutant Plk protein are provided. A method for detecting an abnormal cell which comprises the step of detecting the mutant Plk protein or the gene encoding the protein is also provided.

Abstract: A mutant Plk protein having a mutation in C-terminal domain thereof specified by amino acid residues of from 439 to 603 of amino acid sequence of wild-type Plk protein wherein said mutation decreases affinity with Hsp90 protein, and a gene encoding said mutant Plk protein are provided. A method for detecting an abnormal cell which comprises the step of detecting the mutant Plk protein or the gene encoding the protein is also provided.

Abstract: In a conductive member having a support and provided thereon at least one cover layer, the cover layer has a surface layer, and the surface layer contains fine particles. In the surface layer, fine particles present at the surface layer lower part corresponding to a range within 30% of the total layer thickness from the lowermost plane have an average particle diameter which is larger than the average particle diameter of fine particles present at the surface layer upper part corresponding to a range within 30% of the total layer thickness from the uppermost plane. A process cartridge and an electrophotographic apparatus have such a conductive member.

Abstract: A compound represented by the following formula (I) or a salt thereof and a medicament such as an angiogenesis inhibitor and an antitumor agent which comprises said compound or a physiologically acceptable salt thereof as an active ingredient.

Abstract: A mutant Plk protein having a mutation in C-terminal domain thereof specified by amino acid residues of from 439 to 603 of amino acid sequence of wild-type Plk protein wherein said mutation decreases affinity with Hsp90 protein, and a gene encoding said mutant Plk protein are provided. A method for detecting an abnormal cell which comprises the step of detecting the mutant Plk protein or the gene encoding the protein is also provided.

Abstract: An anti-tumor composition containing cytotrienin (I), (II), (III) or (IV) as the active ingredient, which compounds are produced by culturing a bacterium which produces cytotrienin (I), (II), (III) or (IV), in a medium and accumulating cytotrienin (I), (II), (III) or (IV) in the medium and harvesting the product.

Abstract: An intermediate transfer member for receiving a toner image formed on a first image-bearing member and transferring the toner image onto a second image-bearing member has a surface coated with at least one of a nitrate ion adsorbent and a compound having a layer structure, whereby a scattering of toner particles during a successive image formation is effectively suppressed for a long period.